IP Library Granted Patent US 12,187,736
Granted Patent B2
US 12,187,736 · App. 18/220,484 · Granted Jan 7, 2025

Selective estrogen receptor degraders and uses thereof

Inventors: Xing Dai (Short Hills, NJ); Yaolin Wang (Short Hills, NJ)
Assignee: InventisBio LLC
C07D495/04A61P5/32A61P35/00C07D471/04C07D471/14C07D491/048
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,187,736
App. No.
18/220,484
Granted
Jan 7, 2025
Kind
B2
Abstract

The present disclosure provides compounds of Formula (I) and Formula (II). The compounds described herein may be useful in treating proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Claims (39)

1. A compound of Formula C2:

or a pharmaceutically acceptable salt thereof,

wherein:

A is —CR A ═ or —N═, as valency permits;

W is —NH—, —O—, or —S—;

X is Cl, Br, or I;

a is 1, 2, or 3;

each instance of R 1 is independently hydrogen, halogen, substituted or unsubstituted alkyl, —OR A , or —CN;

R 2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl;

R 3 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, -OR A or -N(R B ) 2 ;

R 4 is hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, -OR A or -N(R B ) 2 , or R 3 and R 4 are taken together with the intervening atoms to form substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl;

R 8 is hydrogen, halogen, or methyl;

R A1 is substituted or unsubstituted alkyl, chlorine, or fluorine;

R A2 is substituted or unsubstituted alkyl, chlorine, or fluorine, wherein: (i) either R A1 or R A2 is chlorine; or (ii) one of R A1 and R A2 is fluorine, and the other one of R A1 and R A2 is selected from the group consisting of substituted or unsubstituted alkyl, chlorine, and fluorine;

R A is hydrogen or substituted or unsubstituted alkyl, or oxygen protecting group; and

R B is hydrogen or substituted or unsubstituted alkyl, nitrogen protecting group, or optionally two R B are taken together with the intervening atoms to form substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl,

wherein when both R A1 and R A2 are fluorine, the compound further satisfies at least one of the following conditions:

W is O or S;

at least one of R 1 is not hydrogen;

R 2 is not hydrogen or methyl;

A is —N═; or

R 3 and R 4 are taken together with the intervening atoms to form substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is —CH═ or —N═.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein W is —NH—.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein a is 1.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least one instance of R 1 is hydrogen.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least one instance of R 1 is fluorine or chlorine.

7. The compound of claim 1 , wherein at least one instance of R 1 is —OR A , in which R A is hydrogen or substituted or unsubstituted C 1-6 alkyl.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least one instance of R 1 is —OH, —OMe, or substituted or unsubstituted C 1-6 alkyl.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is substituted or unsubstituted C 1-6 alkyl.

10. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein R 2 is methyl, ethyl, or —CF 3 .

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least one of R 3 , R 4 , R 8 , is independently selected from the group consisting of hydrogen, fluorine, and substituted or unsubstituted C 1 -C 6 alkyl.

12. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 are taken together with the intervening atom(s) to form substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl.

13. The compound of claim 12 , or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 are taken together with the intervening atom(s) to form substituted or unsubstituted cyclopropyl.

14. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein at least one of R A1 and R A2 is chlorine.

15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R A1 is fluorine, and R A2 is substituted or unsubstituted C 1 -C 6 alkyl or chlorine.

16. The compound of claim 15 , or a pharmaceutically acceptable salt thereof, wherein R A1 is fluorine and R A2 is methyl.

17. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R A1 is fluorine and R A2 is fluorine.

18. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R A1 is chlorine and R A2 is chlorine.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2024
From: DAI, XING; WANG, YAOLIN
To: SHANGHAI SHALETECH TECHNOLOGY, INC.
Reel/Frame 069376/0882 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2024
From: SHANGHAI SHALETECH TECHNOLOGY, INC.
To: INVENTISBIO INC.
Reel/Frame 069376/0889 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2024
From: INVENTISBIO INC.
To: INVENTISBIO LLC
Reel/Frame 069376/0955 →
Continuity (5)
Continuation 17241722 · Apr 27, 2021
Continuation 16655689 · Oct 17, 2019
Continuation 16073673
Provisional Application 62291921 · Feb 5, 2016
Related Publication 20240043442A1 · Feb 8, 2024
References Cited (45)
US 9980947B2 · Labadie et al. · 2018 [cited by applicant]
US 10647724B2 · Dai et al. · 2020 [cited by applicant]
US 11014936B2 · Dai et al. · 2021 [cited by applicant]
US 11241418B2 · Dai et al. · 2022 [cited by applicant]
US 20030225132A1 · DiNinno et al. · 2003 [cited by applicant]
US 20140107095A1 · Kahraman et al. · 2014 [cited by applicant]
US 20140357661A1 · Bradbury et al. · 2014 [cited by applicant]
US 20150005286A1 · Smith et al. · 2015 [cited by applicant]
US 20150258099A1 · Hager et al. · 2015 [cited by applicant]
US 20170362228A1 · Labadie et al. · 2017 [cited by applicant]
US 20180002344A1 · Labadie et al. · 2018 [cited by applicant]
US 20180021316A1 · Scott et al. · 2018 [cited by applicant]
CN 105229004A · 2016 [cited by applicant]
EP 3312184A1 · 2018 [cited by applicant]
EP 3378861A1 · 2018 [cited by applicant]
JP 2007529534 · 2007 [cited by applicant]
WO 2003059346A1 · 2003 [cited by applicant]
WO 2004091488A2 · 2004 [cited by applicant]
WO 2005089764 · 2005 [cited by applicant]
WO 2009064251A1 · 2009 [cited by applicant]
WO 2010138685 · 2010 [cited by applicant]
WO 2010138706A1 · 2010 [cited by applicant]
WO 2014151899A1 · 2014 [cited by applicant]
WO 2014205136A1 · 2014 [cited by applicant]
WO 2014191726A1 · 2014 [cited by applicant]
WO 2015190568A1 · 2015 [cited by applicant]
WO 2016097072A1 · 2016 [cited by applicant]
WO 2016202161A1 · 2016 [cited by applicant]
WO 2017059139A1 · 2017 [cited by applicant]
WO 2017080338A1 · 2017 [cited by applicant]
WO 2017172957A1 · 2017 [cited by applicant]
WO 2017216279A1 · 2017 [cited by applicant]
WO 2017216280A1 · 2017 [cited by applicant]
WO 2018019793A1 · 2018 [cited by applicant]
WO 2018077260A1 · 2018 [cited by applicant]
WO 2018130124A1 · 2018 [cited by applicant]
WO 2018138303A1 · 2018 [cited by applicant]
Extended European Search Report for European Application No. 17748247.8, Munich, Germany, mailed on Jul. 25, 2019, 11 pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017 /016452, Commissioner for Patents, Virginia mailed on Aug. 16, 2018, 6 pages. [cited by applicant]
McDonnell, D.P., et al., “Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer,” Journal of Medicinal Chemistry, 58(12):4883-4887, American Chemical Society, United… [cited by applicant]
Scott, J.S., et al., “Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry,” ACS Medicinal Chemistry Letters, 10(10):1492-1497, American Chemical Society, Unit… [cited by applicant]
Written Opinion for International Application No. PCT/US2017 /016452, Commissioner for Patents, Virginia mailed on Apr. 25, 2017, 4 pages. [cited by applicant]
De Savi et al., “Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1 H-pyrido[3,4-b ]indol-1-y 1)phenyl)acrylic IAcid (AZD9496), a Potent and… [cited by applicant]
International Search Report of PCT/US2017 /0 1 6452 dated Apr. 25, 2017, WIPO. [cited by applicant]
Bragg et al., “The synthesis of tritium, carbon-14 and stable isotope labelled selective estrogen receptor degraders”, Journal of Labelled Compounds and Radiopharmaceuticals, Aug. 24, 2016, 8 pages. [cited by applicant]